<DOC>
	<DOCNO>NCT01416610</DOCNO>
	<brief_summary>This prospective , multi-center , observational study evaluate efficacy safety Pegasys ( peginterferon alfa-2a ) plus Copegus ( ribavirin ) participants previously untreated chronic hepatitis C , genotype 2 , 3 , 1 4 , undergo opioid maintenance therapy . Data collect eligible participant receive Pegasys Copegus treatment prescribe treat physician treatment-free follow-up period 24 week .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Plus Copegus ( Ribavirin ) Participants With Chronic Hepatitis C ( CHC ) , Genotype 2 , 3 , 1 4 , Undergoing Opioid Maintenance Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Participants undergo opioid maintenance therapy Serologic evidence CHC prior therapy CHC genotype 2 , 3 , 1 4 Quantifiable serum hepatitis C ( HCV ) ribonucleic acid ( RNA ) All fertile male female receive ribavirin must use two form effective contraception treatment study drug 7 month completion treatment Harmful use psychoactive substance ( include excessive alcohol consumption ) preclude successful participation study discretion investigator Pegylated interferon , standard interferon ribavirin therapy time prior initiation study Coinfection hepatitis A , hepatitis B Human Immunodeficiency Virus ( HIV ) Current diagnosis major depression psychotic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>